
EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028
Europe Cystic Fibrosis Therapeutics Market by Route of Administration (Inhale, Oral) by Drug Class (CFTR Modulators, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplements) and by Geographiy.
The European cystic fibrosis market is predicted to grow considerably and reach the highest CAGR of 10.10% over the forecast period of 2020-2028. The important factor accelerating the growth of the market is a surge in the incidence of cystic fibrosis in the region. In 2016, as per the European Cystic Fibrosis Society, out of 38,985 individuals suffering from cystic fibrosis, 10,336 were from the UK.
The fast pace of growth of the cystic fibrosis therapeutics market of Europe is analyzed with respect to countries such as Germany, Russia, the United Kingdom, France, Poland, Italy, Belgium, and the rest of Europe. In the UK, increasing awareness among patients regarding early diagnosis of cystic fibrosis, a surge in investment for R&D of various CF drugs, a rise in national newborn screening programs, and many companies developing drugs for individuals who do not get benefitted from CFTR drugs, are the factors fueling the market growth in the region.
In countries like France, the prevalence of cystic fibrosis across the country, along with increasing healthcare spending is anticipated to fuel the market. In Italy, researches on cystic fibrosis are in process, and this growing R&D in the country is estimated to accelerate market growth. Russian government provides insurance for CF, but it does not cover all medications and treatments. This is hindering the market growth in Russia, implying that the market will grow at a stable rate.
GlaxoSmithKline PLC, headquartered in Brentford, Middlesex, UK, is a healthcare company that manufactures, develops, and sells pharmaceuticals, OTC medicines, vaccines, and consumer healthcare products. The company operates across Europe and the US. In November 2019, it was announced that the company would develop the investigational broadly neutralizing antibody for the treatment and prevention of HIV-1.
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- MARKET DEFINITION
- KEY DRIVERS
- ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
- INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
- RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
- KEY RESTRAINTS
- STRINGENT REGULATION
- LOW AWARENESS AMONG DEVELOPING ECONOMIES
- KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
- THREAT OF NEW ENTRY
- THREAT OF SUBSTITUTION
- BUYER’S POWER
- SUPPLIER’S POWER
- COMPETITIVE RIVALRY
- PESTEL ANALYSIS
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY INVESTMENT INSIGHTS
- PORTER’S FIVE FORCE ANALYSIS
- MARKET BY ROUTE OF ADMINISTRATION
- INHALE
- ORAL
- MARKET BY DRUG CLASS
- CFTR MODULATORS
- BRONCHODILATORS
- MUCOLYTIC
- PANCREATIC ENZYME SUPPLEMENTS
- GEOGRAPHICAL ANALYSIS
- EUROPE
- THE UNITED KINGDOM
- FRANCE
- GERMANY
- ITALY
- RUSSIA
- BELGIUM
- POLAND
- REST OF EUROPE
- EUROPE
- COMPANY PROFILES
- ABBOTT LABORATORIES
- ABBVIE INC
- AGILENT TECHNOLOGIES INC
- ALLERGAN PLC
- HOFFMANN-LA ROCHE
- GILEAD SCIENCES INC
- GLAXOSMITHKLINE PLC
- JOHNSON & JOHNSON
- MYLAN N.V
- NOVARTIS AG
- PERKINELMER
- PFIZER INC
- PHARMAXIS LTD
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- VERTEX PHARMACEUTICALS INCORPORATED
TABLE LIST
TABLE 1: MARKET SNAPSHOT – VETERINARY VACCINE
TABLE 2: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
TABLE 3: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 4: EUROPE INHALE MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
TABLE 5: EUROPE INHALE MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 6: EUROPE ORAL MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
TABLE 7: EUROPE ORAL MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 8: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
TABLE 9: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: EUROPE CFTR MODULATORS MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
TABLE 11: LIST OF CFTR MODULATORS GENERIC AND BRAND NAME
TABLE 12: EUROPE CFTR MODULATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 13: EUROPE BRONCHODILATORS MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
TABLE 14: LIST OF BRONCHODILATORS GENERIC AND BRAND NAME
TABLE 15: EUROPE BRONCHODILATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 16: EUROPE MUCOLYTIC MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
TABLE 17: LIST OF MUCOLYTICS GENERIC AND BRAND NAME
TABLE 18: EUROPE MUCOLYTIC MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 19: EUROPE PANCREATIC ENZYME SUPPLEMENTS MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
TABLE 20: EUROPE PANCREATIC ENZYME SUPPLEMENTS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 21: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
TABLE 22: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION):
FIGURES LIST
FIGURE 1: PORTER’S FIVE FORCES ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, IN 2019
FIGURE 6: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY INHALE, 2020-2028 (IN $ MILLION)
FIGURE 7: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ORAL, 2020-2028 (IN $ MILLION)
FIGURE 8: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, IN 2019
FIGURE 9: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY CFTR MODULATORS, 2020-2028 (IN $ MILLION)
FIGURE 10: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY BRONCHODILATORS, 2020-2028 (IN $ MILLION)
FIGURE 11: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY MUCOLYTIC, 2020-2028 (IN $ MILLION)
FIGURE 12: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY PANCREATIC ENZYME SUPPLEMENTS, 2020-2028 (IN $ MILLION)
FIGURE 13: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
FIGURE 14: THE UNITED KINGDOM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
FIGURE 15: FRANCE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
FIGURE 16: GERMANY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
FIGURE 17: ITALY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
FIGURE 18: RUSSIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
FIGURE 19: BELGIUM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
FIGURE 20: POLAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
FIGURE 21: REST OF EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- EUROPE
- THE UNITED KINGDOM
- FRANCE
- GERMANY
- ITALY
- RUSSIA
- BELGIUM
- POLAND
- REST OF EUROPE
- EUROPE
- MARKET BY ROUTE OF ADMINISTRATION
- INHALE
- ORAL
- MARKET BY DRUG CLASS
- CFTR MODULATORS
- BRONCHODILATORS
- MUCOLYTIC
- PANCREATIC ENZYME SUPPLEMENTS
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.